Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance

Nature Cell Biology

Volumn 7, Issue 6, 2005, Pages 591-600

  MacKeigan, Jeffrey P ^a   Murphy, Leon O ^a   Blenis, John ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHATASE; PHOSPHOTRANSFERASE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN GENOME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA INTERFERENCE; SCREENING; UNINDEXED SEQUENCE;

APOPTOSIS; CELL CYCLE PROTEINS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; GROWTH INHIBITORS; HELA CELLS; HUMANS; NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHOTRANSFERASES; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 20444419344     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1258     Document Type: Article

References (43)

1. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. MacKeigan, J.P., Collins, T.S. & Ting, J.P. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem. 275, 38953-38956 (2000).
3. Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
4. MacKeigan, J.P. et al. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin. Cancer Res. 8, 2091-2099 (2002).
5. Pietras, K. et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62, 5476-5484 (2002).
6. Hannon, G.J. & Rossi, J.J. Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378 (2004).
7. Tassi, E., Biesova, Z., Di Fiore, P.P., Gutkind, J.S. & Wong, W.T. Human JIK, a novel member of the STE20 kinase family that inhibits JNK and is negatively regulated by epidermal growth factor. J. Biol. Chem. 274, 33287-33295 (1999).
8. Wishart, M.J., Denu, J.M., Williams, J.A. & Dixon, J.E. A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. J. Biol. Chem. 270, 26782-26785 (1995).
9. Wishart, M.J. & Dixon, J.E. Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Trends Biochem. Sci. 23, 301-306 (1998).
10. Schiff, P.B., Fant, J. & Horwitz, S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277, 665-667 (1979).
11. Schiff, P.B. & Horwitz, S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA 77, 1561-1565 (1980).
12. Sorenson, C.M., Barry, M.A. & Eastman, A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl Cancer Inst. 82, 749-755 (1990).
13. van Maanen, J.M., Retel, J., de Vries, J. & Pinedo, H.M. Mechanism of action of antitumor drug etoposide: a review. J. Natl Cancer Inst. 80, 1526-1533 (1988).
14. Brunet, A. et al. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21, 952-965 (2001).
15. Huang, S. & Houghton, P.J. Inhibitors of mammalian target of rapamycin as novel anti-tumor agents: from bench to clinic. Curr. Opin. Investig. Drugs 3, 295-304 (2002).
16. Bjornsti, M.A. & Houghton, P.J. The TOR pathway: a target for cancer therapy. Nature Rev. Cancer 4, 335-348 (2004).
17. Fingar, D.C. & Blenis, J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171 (2004).
18. Senderowicz, A.M. Small-molecule cyclin-dependent kinase modulators. Oncogene 22, 6609-6620 (2003).
19. Pasleau, F., Grooteclaes, M. & Gol-Winkler, R. Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene 8, 849-854 (1993).
20. Lane, H.A. et al. ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 20, 3210-3223 (2000).
21. Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003).
22. Valente, E.M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004).
23. MacKeigan, J.P. et al. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIα. Cancer Res. 63, 6928-6934 (2003).
24. Cheng, J.Q. et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl Acad. Sci. USA 89, 9267-9271 (1992).
25. Datta, S.R., Brunet, A. & Greenberg, M.E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927 (1999).
26. Storz, P. & Toker, A. Protein kinase D mediates a stress-induced NF-B activation and survival pathway. EMBO J. 22, 109-120 (2003).
27. Yang, B.F., Xiao, C., Roa, W.H., Krammer, P.H. & Hao, C. Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J. Biol. Chem. 278, 7043-7050 (2003).
28. Seton-Rogers, S.E. et al. Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Proc. Natl Acad. Sci. USA 101, 1257-1262 (2004).
29. Muraoka, R.S. et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol. Cell. Biol. 23, 8691-8703 (2003).
30. Siegel, P.M., Shu, W., Cardiff, R.D., Muller, W.J. & Massague, J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl Acad. Sci. USA 100, 8430-8435 (2003).
31. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P.P. Pten is essential for embryonic development and tumour suppression. Nature Genet. 19, 348-355 (1998).
32. Goberdhan, D.C., Paricio, N., Goodman, E.C., Mlodzik, M. & Wilson, C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13, 3244-3258 (1999).
33. Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39 (1998).
34. Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169-1178 (1998).
35. Murphy, L.O., MacKeigan, J.P. & Blenis, J. A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol. Cell. Biol. 24, 144-153 (2004).
36. Alvarez, B., Martinez, A.C., Burgering, B.M. & Carrera, A.C. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413, 744-747 (2001).
37. Wang, Z. et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304, 1164-1166 (2004).
38. Narayan, G. et al. Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 22, 3489-3499 (2003).
39. Brondello, J.M., Pouyssegur, J. & McKenzie, F.R. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286, 2514-2517 (1999).
40. Makin, G. & Dive, C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Breast Cancer Res. 3, 150-153 (2001).
41. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
42. Tartaglia, M. et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature Genet. 29, 465-468 (2001).
43. Mohi, M.G. et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7, 179-191 (2005).